Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer [Abstract]

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Journal of Nuclear Medicine, 56, Supplement 3, S. 1439-

Event: Veröffentlichung

(where): Augsburg

(who): Universität Augsburg

(when): 2015

Event: Veröffentlichung

(where): New York, NY

(who): Society of Nuclear Medicine

(when): 2015

Creator: Bluemel, Christina
Christian, Vollmer
Buck, Andreas
Lapa, Constantin Frederik Victor
Riedmiller, Hubertus
Lassmann, Michael
Schirbel, Andreas
Herrmann, Ken

URN: urn:nbn:de:bvb:384-opus4-637097

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Bluemel, Christina
Christian, Vollmer
Buck, Andreas
Lapa, Constantin Frederik Victor
Riedmiller, Hubertus
Lassmann, Michael
Schirbel, Andreas
Herrmann, Ken
Universität Augsburg
Society of Nuclear Medicine

Time of origin

2015

Other Objects (12)

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Peptide receptor radionuclide therapy for sarcoidosis

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy

$Novel CYP11B-ligand [$^123/131}$I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience$

Novel CYP11B-ligand [$^123/131}$I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography

In vivo targeting of CXCR4 - new horizons

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Peptide receptor radionuclide therapy for sarcoidosis

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy

$Novel CYP11B-ligand [$^123/131}$I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience$

Novel CYP11B-ligand [$^123/131}$I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography

In vivo targeting of CXCR4 - new horizons

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Peptide receptor radionuclide therapy for sarcoidosis

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy

$Novel CYP11B-ligand [$^123/131}$I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience$

Novel CYP11B-ligand [$^123/131}$I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography

In vivo targeting of CXCR4 - new horizons

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Additional value of PSMA-PET/CT in biochemical recurrence during follow-up of patients with prostate cancer [Abstract]

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Peptide receptor radionuclide therapy for sarcoidosis

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy

Novel CYP11B-ligand [\(^123/131}\)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography

In vivo targeting of CXCR4 - new horizons

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Peptide receptor radionuclide therapy for sarcoidosis

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy

Novel CYP11B-ligand [\(^123/131}\)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography

In vivo targeting of CXCR4 - new horizons

Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

"Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging"

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

Peptide receptor radionuclide therapy for sarcoidosis

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy

Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy

Novel CYP11B-ligand [\(^123/131}\)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience

Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography

In vivo targeting of CXCR4 - new horizons

Related objects

Reset password